Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets

Joen Rong Sheu, Ya Chen Kan, Wei Chun Hung, Wun Chang Ko, Mao Hsiung Yen

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Tetramethylpyrazine is the active ingredient of a Chinese herbal medicine. In this study, tetramethylpyrazine was tested for its antiplatelet activities in human platelet suspensions. In human platelets, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited both platelet aggregation and ATP-release reaction induced by a variety of agonists (i.e., ADP, collagen, and U46619). Tetramethylpyrazine (0.5 mM) did not significantly change the fluorescence of platelet membranes labeled with diphenylhexatriene, even at the high concentration (1.5 mM). Furthermore, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited [3H]inositol monophosprate formation stimulated by collagen (5 μg/ml) in [3H]myoinositol loaded platelets. Tetramethylpyrazine (0.5-1.5 mM) also dose-dependently inhibited the intracellular free Ca+2 rise of Fura 2-AM loaded platelets stimulated by collagen (5 μg/ml). Moreover, tetramethylpyrazine (0.5-1.5 mM) inhibited thromboxane B2 formation stimulated by collagen. At a higher concentration (1.0 mM), tetramethylpyrazine has also been shown to influence the binding of FITC-triflavin to platelet glycoprotein IIb/IIIa complex. Triflavin, a specific glycoprotein IIb/IIIa complex antagonist purified from Trimeresurus flavoviridis venom. It is concluded that the antiplatelet activity of tetramethylpyrazine may possibly involve two pathways: 1) at a lower concentration (0.5 mM), tetramethylpyrazine is shown to inhibit phosphoinositide breakdown and thromboxane A2 formation; and 2) at a higher concentration (1.0 mM), it leads to the inhibition of platelet aggregation through binding to the glycoprotein IIb/IIIa complex.

Original languageEnglish
Pages (from-to)259-270
Number of pages12
JournalThrombosis Research
Volume88
Issue number3
DOIs
Publication statusPublished - Nov 1 1997

Fingerprint

Blood Platelets
Platelet Glycoprotein GPIIb-IIIa Complex
Collagen
Inositol
Platelet Aggregation
tetramethylpyrazine
Diphenylhexatriene
Integrin beta3
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Thromboxane B2
Thromboxane A2
Herbal Medicine
Fluorescein-5-isothiocyanate
Fura-2
Phosphatidylinositols
Human Activities
Adenosine Diphosphate
Suspensions
Adenosine Triphosphate
Fluorescence

Keywords

  • Glycoprotein IIb/IIIa complex
  • Intracellular calcium
  • Platelet aggregation
  • Thromboxane A
  • TMPZ

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. / Sheu, Joen Rong; Kan, Ya Chen; Hung, Wei Chun; Ko, Wun Chang; Yen, Mao Hsiung.

In: Thrombosis Research, Vol. 88, No. 3, 01.11.1997, p. 259-270.

Research output: Contribution to journalArticle

Sheu, Joen Rong ; Kan, Ya Chen ; Hung, Wei Chun ; Ko, Wun Chang ; Yen, Mao Hsiung. / Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. In: Thrombosis Research. 1997 ; Vol. 88, No. 3. pp. 259-270.
@article{39d50f2645a4412ba817a79abe1eadcd,
title = "Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets",
abstract = "Tetramethylpyrazine is the active ingredient of a Chinese herbal medicine. In this study, tetramethylpyrazine was tested for its antiplatelet activities in human platelet suspensions. In human platelets, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited both platelet aggregation and ATP-release reaction induced by a variety of agonists (i.e., ADP, collagen, and U46619). Tetramethylpyrazine (0.5 mM) did not significantly change the fluorescence of platelet membranes labeled with diphenylhexatriene, even at the high concentration (1.5 mM). Furthermore, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited [3H]inositol monophosprate formation stimulated by collagen (5 μg/ml) in [3H]myoinositol loaded platelets. Tetramethylpyrazine (0.5-1.5 mM) also dose-dependently inhibited the intracellular free Ca+2 rise of Fura 2-AM loaded platelets stimulated by collagen (5 μg/ml). Moreover, tetramethylpyrazine (0.5-1.5 mM) inhibited thromboxane B2 formation stimulated by collagen. At a higher concentration (1.0 mM), tetramethylpyrazine has also been shown to influence the binding of FITC-triflavin to platelet glycoprotein IIb/IIIa complex. Triflavin, a specific glycoprotein IIb/IIIa complex antagonist purified from Trimeresurus flavoviridis venom. It is concluded that the antiplatelet activity of tetramethylpyrazine may possibly involve two pathways: 1) at a lower concentration (0.5 mM), tetramethylpyrazine is shown to inhibit phosphoinositide breakdown and thromboxane A2 formation; and 2) at a higher concentration (1.0 mM), it leads to the inhibition of platelet aggregation through binding to the glycoprotein IIb/IIIa complex.",
keywords = "Glycoprotein IIb/IIIa complex, Intracellular calcium, Platelet aggregation, Thromboxane A, TMPZ",
author = "Sheu, {Joen Rong} and Kan, {Ya Chen} and Hung, {Wei Chun} and Ko, {Wun Chang} and Yen, {Mao Hsiung}",
year = "1997",
month = "11",
day = "1",
doi = "10.1016/S0049-3848(97)00253-3",
language = "English",
volume = "88",
pages = "259--270",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets

AU - Sheu, Joen Rong

AU - Kan, Ya Chen

AU - Hung, Wei Chun

AU - Ko, Wun Chang

AU - Yen, Mao Hsiung

PY - 1997/11/1

Y1 - 1997/11/1

N2 - Tetramethylpyrazine is the active ingredient of a Chinese herbal medicine. In this study, tetramethylpyrazine was tested for its antiplatelet activities in human platelet suspensions. In human platelets, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited both platelet aggregation and ATP-release reaction induced by a variety of agonists (i.e., ADP, collagen, and U46619). Tetramethylpyrazine (0.5 mM) did not significantly change the fluorescence of platelet membranes labeled with diphenylhexatriene, even at the high concentration (1.5 mM). Furthermore, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited [3H]inositol monophosprate formation stimulated by collagen (5 μg/ml) in [3H]myoinositol loaded platelets. Tetramethylpyrazine (0.5-1.5 mM) also dose-dependently inhibited the intracellular free Ca+2 rise of Fura 2-AM loaded platelets stimulated by collagen (5 μg/ml). Moreover, tetramethylpyrazine (0.5-1.5 mM) inhibited thromboxane B2 formation stimulated by collagen. At a higher concentration (1.0 mM), tetramethylpyrazine has also been shown to influence the binding of FITC-triflavin to platelet glycoprotein IIb/IIIa complex. Triflavin, a specific glycoprotein IIb/IIIa complex antagonist purified from Trimeresurus flavoviridis venom. It is concluded that the antiplatelet activity of tetramethylpyrazine may possibly involve two pathways: 1) at a lower concentration (0.5 mM), tetramethylpyrazine is shown to inhibit phosphoinositide breakdown and thromboxane A2 formation; and 2) at a higher concentration (1.0 mM), it leads to the inhibition of platelet aggregation through binding to the glycoprotein IIb/IIIa complex.

AB - Tetramethylpyrazine is the active ingredient of a Chinese herbal medicine. In this study, tetramethylpyrazine was tested for its antiplatelet activities in human platelet suspensions. In human platelets, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited both platelet aggregation and ATP-release reaction induced by a variety of agonists (i.e., ADP, collagen, and U46619). Tetramethylpyrazine (0.5 mM) did not significantly change the fluorescence of platelet membranes labeled with diphenylhexatriene, even at the high concentration (1.5 mM). Furthermore, tetramethylpyrazine (0.5-1.5 mM) dose-dependently inhibited [3H]inositol monophosprate formation stimulated by collagen (5 μg/ml) in [3H]myoinositol loaded platelets. Tetramethylpyrazine (0.5-1.5 mM) also dose-dependently inhibited the intracellular free Ca+2 rise of Fura 2-AM loaded platelets stimulated by collagen (5 μg/ml). Moreover, tetramethylpyrazine (0.5-1.5 mM) inhibited thromboxane B2 formation stimulated by collagen. At a higher concentration (1.0 mM), tetramethylpyrazine has also been shown to influence the binding of FITC-triflavin to platelet glycoprotein IIb/IIIa complex. Triflavin, a specific glycoprotein IIb/IIIa complex antagonist purified from Trimeresurus flavoviridis venom. It is concluded that the antiplatelet activity of tetramethylpyrazine may possibly involve two pathways: 1) at a lower concentration (0.5 mM), tetramethylpyrazine is shown to inhibit phosphoinositide breakdown and thromboxane A2 formation; and 2) at a higher concentration (1.0 mM), it leads to the inhibition of platelet aggregation through binding to the glycoprotein IIb/IIIa complex.

KW - Glycoprotein IIb/IIIa complex

KW - Intracellular calcium

KW - Platelet aggregation

KW - Thromboxane A

KW - TMPZ

UR - http://www.scopus.com/inward/record.url?scp=0031277778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031277778&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(97)00253-3

DO - 10.1016/S0049-3848(97)00253-3

M3 - Article

C2 - 9526946

AN - SCOPUS:0031277778

VL - 88

SP - 259

EP - 270

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -